| Inhaled combined budesonide–formoterol as needed in mild asthma PM O’Byrne, JM FitzGerald, ED Bateman, PJ Barnes, N Zhong, C Keen, ... New England Journal of Medicine 378 (20), 1865-1876, 2018 | 720 | 2018 |
| As-needed budesonide–formoterol versus maintenance budesonide in mild asthma ED Bateman, HK Reddel, PM O’Byrne, PJ Barnes, N Zhong, C Keen, ... New England Journal of Medicine 378 (20), 1877-1887, 2018 | 585 | 2018 |
| Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial PM O'Byrne, H Metev, M Puu, K Richter, C Keen, M Uddin, B Larsson, ... The Lancet Respiratory Medicine 4 (10), 797-806, 2016 | 249 | 2016 |
| Small airway function, exhaled NO and airway hyper-responsiveness in paediatric asthma C Keen, AC Olin, G Wennergren, P Gustafsson Respiratory medicine 105 (10), 1476-1484, 2011 | 87 | 2011 |
| Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the … PM O'Byrne, JM FitzGerald, ED Bateman, PJ Barnes, J Zheng, ... The Lancet Respiratory Medicine 9 (2), 149-158, 2021 | 75 | 2021 |
| The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions S Jurcevic, C Humfrey, M Uddin, S Warrington, B Larsson, C Keen British journal of clinical pharmacology 80 (6), 1324-1336, 2015 | 68 | 2015 |
| Low levels of CC16 in nasal fluid of children with birch pollen‐induced rhinitis S Johansson, C Keen, A Ståhl, G Wennergren, M Benson Allergy 60 (5), 638-642, 2005 | 57 | 2005 |
| Low levels of exhaled nitric oxide are associated with impaired lung function in cystic fibrosis C Keen, P Gustafsson, A Lindblad, G Wennergren, AC Olin Pediatric pulmonology 45 (3), 241-248, 2010 | 56 | 2010 |
| The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’in mild asthma: study protocols for two randomised … PM O’Byrne, JM FitzGerald, N Zhong, E Bateman, PJ Barnes, C Keen, ... Trials 18, 1-13, 2017 | 55 | 2017 |
| Airway nitric oxide in patients with cystic fibrosis is associated with pancreatic function, Pseudomonas infection, and polyunsaturated fatty acids C Keen, AC Olin, A Edentoft, E Gronowitz, B Strandvik Chest 131 (6), 1857-1864, 2007 | 49 | 2007 |
| Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis C Keen, AC Olin, S Eriksson, A Ekman, A Lindblad, S Basu, C Beermann, ... Journal of pediatric gastroenterology and nutrition 50 (5), 537-544, 2010 | 44 | 2010 |
| Prospective observational study in patients with obstructive lung disease: NOVELTY design HK Reddel, MG de Verdier, A Agustí, G Anderson, R Beasley, EH Bel, ... ERJ open research 5 (1), 2019 | 41 | 2019 |
| Seven pillars of small airways disease in asthma and COPD: supporting opportunities for novel therapies OS Usmani, MLK Han, DA Kaminsky, J Hogg, J Hjoberg, N Patel, ... Chest 160 (1), 114-134, 2021 | 33 | 2021 |
| Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study R Hughes, E Rapsomaniki, C Janson, C Keen, BJ Make, PR Burgel, ... Respiratory Medicine 200, 106921, 2022 | 25 | 2022 |
| Bet v 1‐specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen‐induced intermittent allergic rhinitis C Keen, S Johansson, J Reinholdt, M Benson, G Wennergren Pediatric allergy and immunology 16 (3), 209-216, 2005 | 21 | 2005 |
| Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials TH Myrbäck, S Prothon, K Edman, J Leander, M Hashemi, M Dearman, ... The Lancet Rheumatology 2 (1), e31-e41, 2020 | 17 | 2020 |
| Asthma: moving toward a global children's charter W Lenney, Y Adachi, A Bush, GB Fischer, J Hong, A Ostrem, S Pedersen, ... The Lancet Respiratory Medicine 7 (4), 299-300, 2019 | 13 | 2019 |
| Characterisation of pharmacokinetics, safety and tolerability in a first‐in‐human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway … MW Sadiq, S Asimus, MG Belvisi, W Brailsford, R Fransson, R Fuhr, ... British Journal of Clinical Pharmacology 88 (1), 260-270, 2022 | 10 | 2022 |
| Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD N Karlsson, MJ Atkinson, H Müllerová, M Alacqua, C Keen, R Hughes, ... ERJ Open Research 7 (1), 2021 | 8 | 2021 |
| AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis C Kristensson, A Åstrand, S Donaldson, R Goldwater, R Abdulai, N Patel, ... Journal of Cystic Fibrosis 21 (4), 684-690, 2022 | 5 | 2022 |
